Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Abstract

In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).

Affiliated Institutions

Related Publications

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Publication Info

Year: 2022
Type: article
Volume: 386
Issue: 21
Pages: 1973-1985
Citations: 2157
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2157

OpenAlex

Cite This

APA Style

                            
                                
                                    Patrick M Forde, 
                                
                                    Jonathan Spicer, 
                                
                                    Shun Lu
                                
                                et al.
                            
                            (2022). 
                            Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. 
                            New England Journal of Medicine
                            , 386
                            (21)
                            , 1973-1985.
                            https://doi.org/10.1056/nejmoa2202170
                        

Identifiers

DOI: 10.1056/nejmoa2202170